Gene Therapy Casgevy denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for gene therapy casgevy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Casgevy as "Not FDA-Approved" — and How to Fight Back

Casgevy (exagamglogene autotemcel) is an FDA-approved gene therapy for sickle cell disease and transfusion-dependent beta-thalassemia. A denial citing "not FDA-approved" almost always reflects an administrative error — a claims system lookup that failed to locate the correct product code, a formulary database lag, or a coding mismatch. This is one of the most overturnable denial reasons in the book.

## Why This Denial Is Appealable

UHC's own coverage policies must align with FDA approval status. When the FDA has granted approval, a blanket not-approved denial is factually incorrect and internally inconsistent with the insurer's own policy framework. Federal law reinforces your position: ACA §2719 requires that plans cover FDA-approved treatments under the same standards applied to comparable therapies.

## Federal Appeal Framework

• Internal appeal (Level 1): Submit within 180 days of the denial notice. UHC must respond within 30 days for non-urgent requests or 72 hours for expedited/urgent requests.
• External review: After exhausting internal appeals (or if UHC fails to respond in time), you have the right to an Independent Review Organization (IRO) review under ACA §2719. The external-review window is generally within approximately 4 months of the final internal denial. Expedited external review is available when your condition is urgent.
• ERISA §503: If your plan is employer-sponsored, federal ERISA protections guarantee a full-and-fair review of every denial.

## Documentation to Gather

1. Proof of FDA approval: Print the FDA product approval letter and the current FDA label for Casgevy directly from FDA.gov. Attach these to your appeal. 2. Denial letter analysis: Identify the exact reason code and policy number cited. If the denial references a policy that predates approval, note the effective date discrepancy. 3. Prescriber letter: Your treating hematologist or transplant specialist should confirm the FDA-approved indication under which Casgevy is being prescribed and affirm that the product is not investigational. 4. Diagnosis documentation: Medical records confirming your diagnosis (sickle cell disease or transfusion-dependent beta-thalassemia), disease severity, and the clinical basis for this treatment. 5. Plan documents: Pull your Summary Plan Description (SPD) and any applicable drug benefit rider to confirm the plan's stated coverage of FDA-approved specialty therapies.

## Criteria-Mapping Structure for Your Appeal Letter

To maximize success, structure your appeal as a point-by-point rebuttal:

| UHC Requirement | Your Supporting Evidence | |---|---| | Treatment must be FDA-approved for the stated indication | Attach FDA approval letter + current label | | Diagnosis must match approved indication | Attach diagnostic records + prescriber letter | | Coverage policy must apply to FDA-approved products | Cite plan SPD; note policy cannot override FDA status |

Close your letter by requesting that UHC provide the specific policy language, with effective date, on which the denial is based — and note the discrepancy between that language and the FDA's approval record. Gene therapy denials citing "not FDA-approved" for Casgevy are frequently reversed at the first internal appeal level when the correct documentation is presented.